舌根组织细胞肉瘤根治性放疗:病例报告与文献综述
本文报告一例49岁男性舌根组织细胞肉瘤(HS)患者,接受根治性放疗60 Gy/30次,无病生存超过5年且毒性轻微。据作者所知,这是首例以根治性放疗治疗HS的报道,提示当局限性病变手术并发症风险显著时,放疗可作为替代治疗选择。
要点
- 舌根HS极罕见,本例以根治性放疗60 Gy/30次获无病生存>5年。
- 作者称此为首例根治性放疗治疗HS的报道。
- 局限性HS手术并发症风险大时,放疗可作替代选择。
核心结论
- 舌根局限性组织细胞肉瘤以根治性放疗60 Gy/30次治疗,获得无病生存超过5年且毒性轻微。
- 作者认为这是首例以根治性放疗治疗HS的报道,提示放疗可作为手术并发症风险显著时的替代治疗。
研究设计与样本
- 单个病例报告:49岁男性舌根组织细胞肉瘤患者,接受根治性放疗60 Gy/30次。
- 附文献综述,回顾头颈部HS病例及局限性病变的治疗方式。
主要发现
- 患者接受根治性放疗60 Gy/30次后无病生存超过5年,毒性轻微。
- 文献中局限性HS多采用原发手术联合辅助放疗和/或化疗。
关键数值与推荐
- 本例放疗剂量为60 Gy,分30次给予。
- 治疗后无病生存时间超过5年。
临床怎么用
- 对于局限性HS,当手术潜在并发症风险显著时,可考虑根治性放疗作为替代治疗。
局限性
- 仅为单例病例报告,证据级别有限。
- HS极罕见且目前无既定治疗指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histiocytic sarcoma (HS) is an exceedingly rare and aggressive neoplasm of lymphoid and haematopoietic tissues and expresses histological and phenotypical characteristics of mature histiocytes. There have only been a few cases of documented HS in the head and neck region. Whilst patients with HS often have nodal or disseminated disease, patients can present with localised disease. There are currently no established treatment guidelines, and reported cases of localised disease have been managed with primary surgery and adjuvant radiotherapy and/or chemotherapy. Here we present, the case of a 49 year old man with a HS of the base of tongue treated with radical radiotherapy to a dose of 60 Gy in 30 fractions, achieving disease free survival of greater than 5 years with minimal toxicity. To our knowledge, this is the first reported case of HS treated with radical radiotherapy, and suggests that when the potential morbidity of surgery for localised disease is significant, radiotherapy may represent an alternative treatment.
引用
- Iyizoba-Ebozue Z, Burton C, Prestwich RJD, et al. Histiocytic sarcoma of the base of tongue treated with radical radiotherapy: A case report and review of the literature. Clin Transl Radiat Oncol. 2020. PMID: 32025580. doi:10.1016/j.ctro.2020.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。